-

Shareholder Alert: Robbins LLP Announces It Is Investigating Alpha and Omega Semiconductor Limited (AOSL) for Misleading Shareholders

SAN DIEGO & HAMILTON, Bermuda--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating Alpha and Omega Semiconductor Limited (NASDAQ: AOSL) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. Alpha and Omega designs, develops, and supplies power semiconductor products for computing, consumer electronics, communication, and industrial applications worldwide.

If you suffered a loss as a result of Alpha and Omega's misconduct, click here.

Alpha and Omega Semiconductor Limited (AOSL) Reveals DOJ Investigation

In August 2019, Alpha and Omega filed its full year 2019 financial results, assuring that "despite the ongoing challenges of current market conditions… [the Company] is consistently making progress toward [its] calendar 2021 annual revenue target of $600 million." Then, On February 5, 2020, Alpha and Omega revealed that the U.S. Department of Justice "recently commenced an investigation into the Company's compliance with export control regulations with Huawei and its affiliates" and went on to disclose that as a result, the Department of Commerce had requested a suspension of its product shipments to Huawei, which would consequently reduce revenue by approximately $4 million to $5 million in the March quarter. On this news, Alpha and Omega's stock price fell almost 12% to close at $10.85 per share.

Alpha and Omega Semiconductor Limited (AOSL) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:AOSL

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom